Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Roivant Sciences Ltd.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 39.50 · gapped above the open, then crossed back over prior close. High/low 41.36 at 9:00 am ET, 39.26 at 3:15 pm ET.
Roivant Sciences Ltd. has 4 disclosed suppliers and 2 disclosed customers. Each one is named in an SEC filing, either Roivant Sciences Ltd.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Our subsidiary Immunovant holds the intellectual property rights to IMVT-1402 and batoclimab under a license agreement with HanAll Biopharma Co., Ltd. ("HanAll") (the "HanAll Agreement").”
FILING10-K0001635088-26-000061cik 0001635088
“During the year ended March 31, 2025, we repurchased 128,361,786 shares for an aggregate purchase price of approximately $1.3 billion (including fees and expenses), including 71,251,083 shares repurchased from Sumitomo Pharma Co., Ltd. at $9.10 per share for approximately $648.4 million.”
FILING10-K0001635088-26-000061cik 0001635088
“In August 2023, we completed a transaction with SK Biopharmaceuticals Co., Ltd. ("SK Bio"), a subsidiary of SK, Inc., pursuant to which SK Bio purchased all of our shares in Proteovant in exchange for $47.5 million .”
FILING10-K0001635088-26-000061cik 0001635088
“costs allocated to us under our services agreements with Roivant Sciences Ltd. ("RSL") and Roivant Sciences GmbH ("RSG") (the "Services Agreements");”
FILING10-K0001764013-26-000064cik 0001764013disclosed by IMVT
“• Mosliciguat (Pulmovant): up to a maximum of $280.0 million to Bayer upon the achievement of certain development, regulatory and commercial milestone events and tiered high-single-digits royalty on net sales.”
FILING10-K0001635088-26-000061cik 0001635088
“• Brepocitinib (Priovant) : mid tens-of-millions sales milestone payment to Pfizer if aggregate net sales in a given year exceed a mid-hundreds-of-millions amount and tiered sub-teens royalty on net sales.”
FILING10-K0001635088-26-000061cik 0001635088
Watchlist prices, news filtered to it, and its next report on your desk.
ROIV (Roivant Sciences Ltd.) has 4 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: IMVT −3.08%, in healthcare.